NCT00042653已完成3 期
A Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic Kidney Disease (Hemodialysis and Peritoneal Dialysis)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 380
- 主要终点
- To evaluate the efficacy of AMG 073 compared with placebo by determining the proportion of subjects with a mean intact parathyroid hormone (iPTH) value <= 250 pg/mL (26.5 pmol/L) during the efficacy assessment phase.
研究概览
简要总结
This 6 month study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
AMG 073
Experimental
AMG 073
干预措施: AMG 073 (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
To evaluate the efficacy of AMG 073 compared with placebo by determining the proportion of subjects with a mean intact parathyroid hormone (iPTH) value <= 250 pg/mL (26.5 pmol/L) during the efficacy assessment phase.
时间窗: Efficacy Assessment phase - final 10 weeks of study
次要结局
- To evaluate the efficacy of AMG 073 compared with placebo by determining: the proportion of subjects with a reduction from baseline in mean iPTH of >= 30% during the efficacy assessment phase(Efficacy Assessment phase - final 10 weeks of study)
- To evaluate the efficacy of AMG 073 compared with placebo by determining: percentage change from baseline in iPTH during the efficacy assessment phase(Efficacy Assessment phase - final 10 weeks of study)
- To evaluate the safety of AMG 073 compared with placebo(Entire study - 26 weeks)
研究者
相似试验
已完成
3 期
Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)Prostatic HyperplasiaBenign Prostatic HyperplasiaNCT00527605GlaxoSmithKline253
终止
2 期
LYT-100 in Patients With BCRLBreast Cancer Related LymphoedemaLymphoedemaNCT04243837PureTech50
已完成
2 期
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute SchizophreniaSchizophreniaNCT00905307Otsuka Pharmaceutical Development & Commercialization, Inc.459
已完成
3 期
Lurasidone Pediatric Autism StudyAutismNCT01911442Sumitomo Pharma America, Inc.150
已完成
2 期
Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)Erythropoietic ProtoporphyriaNCT01097044Clinuvel Pharmaceuticals Limited77